Spyre Therapeutics prices $350 mln follow-on share sale
Shares of Spyre Therapeutics were down 4.1% premarket after the biotech firm priced a $350 million follow-on share offering at $85 per share, an 8.3% discount to the last sale.
2 mln shares outstanding prior to offering * At Mon close, stock surged 183% YTD * 16 of 17 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $123, per LSEG data (Lance Tupper is a Reuters market analyst. com 1-646-279-6380)